AZD0156: Selective ATM Inhibitor for Advanced Cancer Research

AZD0156 and the Principle of ATM Kinase Inhibition

ATM kinase is a master regulator of the cellular DNA damage response (DDR), orchestrating the detection and repair of DNA double-strand breaks (DSBs) and maintaining genomic stability. Dysregulation of ATM signaling is implicated in cancer progression, therapeutic resistance, and genomic instability. AZD0156 (CAS: 1821428-35-6) is a next-generation, orally bioavailable small-molecule ATM kinase inhibitor developed to deliver sub-nanomolar potency and unmatched selectivity (>1000-fold) for ATM over other PIKK family kinases.

As a potent ATM kinase inhibitor, AZD0156 blocks ATM-dependent phosphorylation cascades, impeding DNA double-strand break repair, modulating checkpoint control, and sensitizing tumor cells to DNA-damaging agents. Its high selectivity profile ensures minimal off-target effects, making it the preferred selective ATM inhibitor for cancer research. Quality control by HPLC and NMR (purity >98%) and robust solubility data support rigorous, reproducible workflows. APExBIO is the trusted supplier for research-grade AZD0156, ensuring reliability and consistency across experiments.

Step-by-Step Experimental Workflow: Integrating AZD0156

1. Compound Preparation and Handling

• Solubility: Dissolve AZD0156 in DMSO at concentrations ≥23.1 mg/mL with gentle warming; moderately soluble in ethanol (≥5.49 mg/mL); insoluble in water.
• Storage: Store powder at -20°C; avoid long-term storage of prepared solutions—use promptly for maximal activity.
• Quality Control: Confirm solution clarity and absence of particulates; reference supplier-provided HPLC and NMR data for purity verification.

2. Cell-Based Assays

• Cell Line Selection: Use ATM-proficient and ATM-deficient cell lines to benchmark specificity and on-target effects.
• Dosing Strategy: Titrate AZD0156 (commonly 10 nM to 1 μM) in single-agent or combination regimens (e.g., with topoisomerase inhibitors, ionizing radiation, or PARP inhibitors).
• Endpoint Readouts: Quantify DDR markers (γH2AX, p-CHK2), cell cycle arrest (flow cytometry), and apoptosis (Annexin V/PI staining). Monitor for potentiation of DNA damage and impaired DSB repair efficiency.

3. In Vivo Studies

• Formulation: Prepare oral dosing solutions in DMSO/PEG or similar vehicle; ensure dose stability and homogeneous suspension.
• Dosing Regimen: Typical oral dosing in preclinical models ranges from 5 to 50 mg/kg, depending on tumor model and combination partners.
• Pharmacodynamics: Assess tumor ATM pathway inhibition via immunohistochemistry or Western blot for ATM substrate phosphorylation. Monitor antitumor efficacy (tumor volume, survival curves).

4. Data Interpretation and Controls

• Include vehicle and DNA-damaging agent controls to contextualize the impact of ATM inhibition.
• Parallel testing with other DDR inhibitors (e.g., ATR, DNA-PK inhibitors) can map functional redundancies and highlight unique roles of ATM.

Advanced Applications and Comparative Advantages

AZD0156’s high selectivity and potency enable precise mechanistic studies and translational workflows in cancer therapy research:

• Combinatorial Therapy Studies: AZD0156 synergizes with genotoxic agents (such as topoisomerase inhibitors or ionizing radiation), enhancing tumor cell kill by disabling DNA double-strand break repair and checkpoint recovery. Quantitatively, preclinical models demonstrate that AZD0156 increases the efficacy (e.g., tumor regression rates, time to progression) of DNA-damaging agents by up to 3-fold compared to monotherapies (see use-case analysis).
• DDR Pathway Dissection: By selectively blocking ATM, researchers can delineate the contributions of ATM versus ATR or DNA-PK in cellular response to DSBs, as highlighted in complementary mechanistic studies.
• Metabolic Adaptation and Genomic Stability: Recent thought-leadership (AZD0156 and the Next Frontier in Cancer Research) demonstrates AZD0156’s role in uncovering metabolic vulnerabilities tied to DDR inhibition, opening avenues in synthetic lethality and precision oncology.

Compared with earlier-generation ATM inhibitors or less selective DDR modulators, AZD0156 exhibits a superior inhibition profile with minimal off-target PIKK activity, supporting cleaner mechanistic readouts and facilitating downstream omics analyses.

Experimental Workflow Enhancements: Lessons from Pharmacologic Profiling

The systematic molecular and pharmacologic evaluation of kinase inhibitors, as exemplified by the study by Kostaras et al., underscores the importance of isoform selectivity, resistance profiling, and combinatorial testing in kinase-targeted cancer research. While their focus was on AKT inhibitors, the methodology—integrating in vitro pharmacology, molecular profiling, and structural modeling—directly informs ATM kinase inhibitor workflows:

• Isoform Selectivity: AZD0156’s >1000-fold selectivity for ATM over other PIKK kinases (e.g., ATR, DNA-PK) ensures that observed phenotypes are ATM-dependent, minimizing confounding effects seen with less selective inhibitors.
• Combination Design: Just as distinct AKT inhibitors produced unique phosphoproteomic signatures and combinatorial synergies, AZD0156 can be paired with agents (like PARP inhibitors) to map synthetic lethality and resistance mechanisms.
• Mutation Impact: Profiling ATM mutant variants in cell-based systems mimics the resistance analysis performed for AKT inhibitors, helping anticipate clinical escape pathways.

Troubleshooting and Optimization Tips

• Solubility Issues: If AZD0156 does not dissolve completely in DMSO, apply gentle warming (≤37°C) and vortexing. Avoid repeated freeze-thaw cycles; aliquot stocks as needed.
• Compound Stability: Use freshly prepared solutions; avoid storing for more than 24 hours, even at -20°C. Degradation can compromise potency and selectivity.
• Cell Viability Artifacts: High DMSO concentrations (>0.5%) can confound viability assays; keep final DMSO below 0.1% when possible.
• On-Target Verification: Rescue experiments with ATM knockdown/knockout models confirm specificity. Parallel use of other PIKK inhibitors can help distinguish ATM-specific effects.
• Batch Consistency: Source AZD0156 from APExBIO for validated lot-to-lot consistency, supported by comprehensive QC data.

For additional workflow optimization, the article AZD0156: Next-Generation ATM Kinase Inhibitor Empowering... offers strategic insights into checkpoint control modulation and combinatorial approaches, complementing the protocols outlined here.

Future Outlook: Expanding the Impact of ATM Inhibition

The integration of AZD0156 into cancer therapy research is rapidly advancing beyond traditional cytotoxicity assays. Emerging directions include:

• Precision Medicine: Biomarker-driven patient stratification for ATM inhibitor-responsive tumors.
• Integration with Multi-Omics Platforms: Leveraging AZD0156 in transcriptomic, proteomic, and metabolomic screens to map DDR network rewiring and therapeutic vulnerabilities.
• Expanding Combinatorial Regimens: Rational pairing with immune checkpoint inhibitors and novel DNA repair modulators to enhance therapeutic windows.
• Clinical Translation: Ongoing early-phase trials are evaluating the safety and efficacy of AZD0156 in advanced cancer settings, informed by robust preclinical data and refined workflows described above.

AZD0156’s best-in-class selectivity and performance profile position it at the forefront of genomic stability regulation and cancer therapy research, enabling transformative discoveries in DDR biology and translational oncology. For researchers committed to dissecting DNA damage response pathways, APExBIO’s AZD0156 is an indispensable tool for the next generation of precision oncology studies.